| Identification | Back Directory | [Name]
trans-4-[4-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid | [CAS]
892489-52-0 | [Synonyms]
AZD-3988
AZD-3988; AZD3988; AZD 3988
trans-4-[-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid
trans-4-[4-[[[5-[(3,4-Difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]cyclohexaneacetic acid
Cyclohexaneacetic acid, 4-[4-[[[5-[(3,4-difluorophenyl)amino]-1,3,4-oxadiazol-2-yl]carbonyl]amino]phenyl]-, trans- | [Molecular Formula]
C23H22F2N4O4 | [MDL Number]
MFCD13184802 | [MOL File]
892489-52-0.mol | [Molecular Weight]
456.44 |
| Chemical Properties | Back Directory | [density ]
1.402 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble to 100 mM in DMSO and to 10 mM in 1eq. NaOH with gentle warming | [form ]
Powder | [pka]
4.72±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AZD 3988 is a diacylglycerol O-acyltransferase (DGAT) enzyme inhibitor, which has been investigated as potential treatments for diabetes and other metabolic diseases. | [in vivo]
AZD3988 (compound 53) shows (i.v., p.o.; 0.5, 1, 2, 5 mg/kg) has good pharmacokinetics in vivo efficacy[1]. | Animal Model: | Mouse, Rats and Dog[1] | | Dosage: | 0.5, 1, 2, 5 mg/kg | | Administration: | IV at 0.5 mg/kg (mouse), 2 mg/kg (rat) and 1 mg/kg (dog) and po at 1 mg/kg (mouse), 5 mg/kg(rat) and 1 mg/kg (dog) | | Result: | | Species | Clp (mL/min/kg) | Vdss(L/kg) | IV half-life (h) | po half-life (h) | po Cmax(lM) | Bioavailability (%) | | Mouse | 4.6 | 0.99 | 4.9 | 4.7 | 1.9 | >100 | | Rat | 1.1 | 0.35 | 3.4 | 5.8 | 20 | >100 | | Dog | 2.5 | 0.36 | 1.8 | 5.7 | 1.5 | 32 |
|
| [storage]
Store at +4°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|